Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities.
Struski
S
S
Gervais
C
C
Helias
C
C
Herbrecht
R
R
Audhuy
B
B
Mauvieux
L
L
D001402:B-Lymphocytes / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured / Q000187:drug effects / Q000648:ultrastructure; D002869:Chromosome Aberrations; D002871:Chromosome Banding / Q000379:methods; D015331:Cohort Studies; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007376:Interleukin-2 / Q000494:pharmacology*; D007621:Karyotyping / Q000379:methods*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects*; D016393:Lymphoma, B-Cell / Q000235:genetics / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000235:genetics / Q000473:pathology*; D008297:Male; D008677:Metaphase; D008934:Mitogens / Q000494:pharmacology*; D009841:Oligonucleotides / Q000494:pharmacology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
C539572:CpG-ODN DSP30; D007376:Interleukin-2; D008934:Mitogens; D009841:Oligonucleotides; D013755:Tetradecanoylphorbol Acetate